
Drug regulations in the United States require that all clinical events reported associated with a marketed drug be collected by the manufacturer and provided to the regulatory zzso In the clinical setting, many factors determine zzso the likelihood of an event being zzso zzso the attribution of the event to the drug, and zzso the actual spontaneous reporting of the drug event association to the manufacturer, regulator or to the zzso In formal zzso trials to collect information on events occurring in drug exposed patients, the events detected are greatly determined by characteristics of the trial zzso The further analysis of events suspected to be adverse drug effects is zzso Once an adverse effect is hypothesized, a number of factors will determine whether it can be further studied in a zzso cost effective zzso 

